Lorlatinib: a new-generation drug for ALK-positive NSCLC

Affiliations

¹ Division of Medical Oncology, Washington University School of Medicine, St Louis, MO 63110, USA.
² Division of Medical Oncology, Washington University School of Medicine, St Louis, MO 63110, USA. Electronic address: danielmorgensztern@wustl.edu.

Comment

Saiama N Waqar et al. Lancet Oncol. 2018 Dec.

. 2018 Dec;19(12):1555-1557.

doi: 10.1016/S1470-2045(18)30789-7. Epub 2018 Nov 6.

¹ Division of Medical Oncology, Washington University School of Medicine, St Louis, MO 63110, USA.
² Division of Medical Oncology, Washington University School of Medicine, St Louis, MO 63110, USA. Electronic address: danielmorgensztern@wustl.edu.

No abstract available

Comment on

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Solomon BJ, et al. Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413378 Clinical Trial.